1. Home
  2. XLO vs RAND Comparison

XLO vs RAND Comparison

Compare XLO & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$16.90

Market Cap

41.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
XLO
RAND
Founded
2016
1969
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
41.8M
41.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
XLO
RAND
Price
$0.65
$16.90
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
528.0K
4.7K
Earning Date
11-13-2025
11-07-2025
Dividend Yield
N/A
7.27%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,804,000.00
$7,327,287.00
Revenue This Year
$589.60
N/A
Revenue Next Year
$38.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
588.40
N/A
52 Week Low
$0.62
$13.25
52 Week High
$1.70
$31.89

Technical Indicators

Market Signals
Indicator
XLO
RAND
Relative Strength Index (RSI) 32.82 80.23
Support Level $0.68 $15.65
Resistance Level $0.73 $15.49
Average True Range (ATR) 0.04 0.56
MACD -0.01 0.29
Stochastic Oscillator 10.24 94.22

Price Performance

Historical Comparison
XLO
RAND

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

Share on Social Networks: